BeOne Medicines Ltd.
Tremor tracks 52 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Aug 3, 2026+1.7
Trials
- ONCBeiGene12Calm
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
FinishedPhase 2118 patientsMain results: May 30, 2025 - ONCBeiGene12Calm
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Running, no new patientsPhase 1/2113 patientsMain results: May 27, 2025 - ONCBeiGene12Calm
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 3453 patientsMain results: Aug 21, 2023 - ONCBeiGene12Calm
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Running, no new patientsPhase 2100 patientsMain results: Jan 24, 2025 - ONCBeOne Medicines2Calm
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
Not started yetPhase 2100 patientsMain results: Mar 31, 2028 - ONCBeiGene2Calm
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
FinishedPhase 2418 patientsMain results: Dec 19, 2025 - ONCBeOne Medicines2Calm
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Signing up patientsPhase 3300 patientsMain results: Aug 31, 2028 - ONCBeOne Medicines2Calm
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Signing up patientsPhase 1/2246 patientsMain results: Nov 2026 - ONCBeOne Medicines2Calm
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Signing up patientsPhase 1/2258 patientsMain results: Nov 30, 2029 - ONCBeOne Medicines2Calm
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Not started yetPhase 1/230 patientsMain results: Apr 30, 2030 - ONCBeOne Medicines2Calm
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Signing up patientsPhase 230 patientsMain results: Feb 28, 2028 - ONCBeOne Medicines2Calm
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Signing up patientsPhase 31,056 patientsMain results: Apr 2029 - ONCBeiGene2Calm
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Signing up patientsPhase 2200 patientsMain results: Nov 2026 - ONCBeOne Medicines2Calm
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Signing up patientsPhase 3630 patientsMain results: Sep 30, 2029 - ONCBeOne Medicines2Calm
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Signing up patientsPhase 1/2146 patientsMain results: Jun 30, 2027 - ONCBeOne Medicines2Calm
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Running, no new patientsPhase 2114 patientsMain results: Sep 22, 2026 - ONCBeOne Medicines2Calm
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Signing up patientsPhase 230 patientsMain results: Dec 31, 2031 - ONCBeOne Medicines2Calm
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Running, no new patientsPhase 3799 patientsMain results: Jul 2028 - ONCBeOne Medicines2Calm
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Running, no new patientsPhase 3652 patientsMain results: Feb 2032 - ONCBeOne Medicines2Calm
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Signing up patientsPhase 3351 patientsMain results: Oct 30, 2027 - ONCBeOne Medicines2Calm
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Signing up patientsPhase 1/2689 patientsMain results: Mar 2027 - ONCBeOne Medicines2Calm
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Running, no new patientsPhase 3510 patientsMain results: Apr 27, 2026 - ONCBeOne Medicines2Calm
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Signing up patientsPhase 3250 patientsMain results: May 15, 2028 - ONCBeOne Medicines2Calm
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Signing up patientsPhase 3500 patientsMain results: Apr 17, 2028 - ONCBeOne Medicines2Calm
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Signing up patientsPhase 3500 patientsMain results: Feb 2031 - ONCBeOne Medicines2Calm
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma
Not started yetPhase 3492 patientsMain results: Sep 21, 2029 - ONCBeOne Medicines2Calm
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Running, no new patientsPhase 1/2125 patientsMain results: Jul 18, 2025 - ONCBeOne Medicines2Calm
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Signing up patientsPhase 1/2630 patientsMain results: Mar 31, 2027 - ONCBeOne Medicines2Calm
A Study of BGB-11417 in Participants With Myeloid Malignancies
Signing up patientsPhase 1/2260 patientsMain results: Aug 31, 2028 - ONCBeOne Medicines2Calm
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Signing up patientsPhase 1/280 patientsMain results: Dec 2, 2028 - ONCBeOne Medicines2Calm
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Not started yetPhase 3600 patientsMain results: Nov 30, 2029 - ONCBeiGene2Calm
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
FinishedPhase 1/271 patientsMain results: Dec 7, 2023 - ONCBeiGene2Calm
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
FinishedPhase 2160 patientsMain results: Jun 17, 2025 - ONCBeOne Medicines2Calm
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Running, no new patientsPhase 3955 patientsMain results: Dec 31, 2026 - ONCBeOne Medicines2Calm
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Running, no new patientsPhase 3153 patientsMain results: Nov 30, 2029 - ONCBeiGene2Calm
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Running, no new patientsPhase 1/2113 patientsMain results: May 23, 2025 - ONCBeOne Medicines2Calm
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Running, no new patientsPhase 294 patientsMain results: Nov 2026 - ONCBeiGene2Calm
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Running, no new patientsPhase 3420 patientsMain results: Jun 30, 2027 - ONCBeOne Medicines2Calm
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
FinishedPhase 3404 patientsMain results: May 23, 2026 - ONCBeiGene2Calm
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
FinishedPhase 3370 patientsMain results: Jan 8, 2025 - ONCBeiGene2Calm
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
FinishedPhase 1/2147 patientsMain results: Feb 6, 2025 - ONCBeiGene2Calm
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
FinishedPhase 265 patientsMain results: Mar 31, 2025 - ONCBeiGene2Calm
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Running, no new patientsPhase 3224 patientsMain results: Dec 1, 2025 - ONCBeiGene2Calm
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Running, no new patientsPhase 3590 patientsMain results: May 7, 2021 - ONCBeiGene2Calm
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
FinishedPhase 1/297 patientsMain results: Aug 28, 2024 - ONCBeiGene2Calm
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
FinishedPhase 2121 patientsMain results: Dec 13, 2024 - ONCBeiGene2Calm
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
FinishedPhase 296 patientsMain results: Jan 9, 2026 - ONCBeiGene2Calm
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
FinishedPhase 235 patientsMain results: Dec 31, 2024 - ONCBeiGene2Calm
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
FinishedPhase 2272 patientsMain results: Sep 4, 2024 - ONCBeiGene2Calm
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
FinishedPhase 1/253 patientsMain results: Aug 30, 2024 - ONCBeiGene2Calm
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
FinishedPhase 284 patientsMain results: Feb 22, 2024 - ONCBeiGene2Calm
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
FinishedPhase 294 patientsMain results: Feb 1, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
167 sales (42 not pre-planned) · 0 purchases
- Wang XiaodongBoard member · Oct 27, 2026Sold 880 sharesabout $313 thousand · pre-planned
- Wang XiaodongBoard member · Oct 27, 2026Sold 1,440 sharesabout $512 thousand · pre-planned
- Wang XiaodongBoard member · Oct 27, 2026Sold 1,239 sharesabout $443 thousand · pre-planned
- Wang XiaodongBoard member · Oct 27, 2026Sold 1,681 sharesabout $603 thousand · pre-planned
- Wang XiaodongBoard member · Oct 27, 2026Sold 1,280 sharesabout $460 thousand · pre-planned
- Wang XiaodongBoard member · Oct 27, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.